Company*
(Country;
Symbol)
Product Description Indication Status
(Date)

AUTOIMMUNE
Abbott
Laboratories
(NYSE:ABT)
Humira (FDA-approved)Adalimumab; fully human antibody designed to block TNF-alpha Moderate to severe psoriasis Phase III data demonstrated the efficacy of Humira both on a short-term and sustained basis (2/2)
BioMS Medical
Corp.
(Canada;
TSX:MS)
MBP8298Synthetic peptideSecondary progressive multiple sclerosisBegan the open-label, follow-on portion to its MAESTRO-01 pivotal Phase II/III trial (2/27)
Centocor Inc.
(unit of Johnson
& Johnson
)
Remicade (FDA-approved)Infliximab; monoclonal antibody that targets tumor necrosis factor alphaModerate to severe plaque psoriasisPhase III data demonstrated statistically significant improvements in productivity, which correlated with improvements in health- related quality of life (2/2)
Centocor Inc.
(unit of Johnson
& Johnson
)
CNTO 1275IL-12/23 mAb; subcutaneous injectionsSevere plaque psoriasis Phase II data showed patients experienced significant clearance of skin disease and signifcant improvements in quality of life (2/8)
Human Genome
Sciences Inc.
(HGSI) and
GlaxoSmithKline
plc
(UK)
LymphoStat-B stimulatorBelimumab; human monoclonal antibody that inhibits activity of B-lymphocyteSystemic lupus erythematosusStarted the first of two pivotal Phase III trials with about 810 patients (2/13)
La Jolla
Pharmaceutical
Co.
(LJPC)
RiquentAbetimus sodium; B-cell toleragen; designed toreduce levels of antibodies to double-stranded DNALupus renal disease Company is changing its ongoing Phase III trial, increasing the number of patients from 600 to 730, focusing on higher doses and combining data from the Phase II pharmacology study with the Phase III study (2/1)
Lux
Biosciences Inc.*
LX211A next-generation calcineurin inhibitorActive Uveitis Began pivotal testing (2/20)
Opexa
Therapeutics
Inc.
(OPXA)
T-cell vaccine technologyRheumatoid arthritisData from a 15-patient trial demonstrated that the technology was well tolerated and induced T cell regulatory immune responses, which correlated with substantial clinical improvements (2/6)
Targeted
Genetics Corp.
(TGEN)
tgAAC94Product using an adeno-associated viral vector to deliver a soluble TNF- alpha receptor proteinInflammatory arthritisPhase I/II data support the safety and tolerability of a single and repeated intra-articular injection of tgAAC94 to affected joints (2/12)
CANCER
Adnexus
Therapeutics
Inc.*
CT-322Anti-angiogenic biologic based on AdNectin protein that blocks vascular endothelial growth factorreceptor-2Advanced cancer Phase I data demonstrated promising evidence of biological activity within four hours of administration, as shown by elevated plasma levels of biomarkers of VEGFR-2 pathway (2/2)
Algeta ASA*
(Norway)
AlpharadinRadiotherapy based on radium-223 Hormone-refractory prostate cancerPhase II data showed patients survived on median nearly 25 weeks (53%) longer than those receiving placebo (2/26)
Antisoma plc
(UK; LSE:ASM)
AS1404Small molecule derived from xanthenone acetic acid; vascular disrupting agentHormone-refractory prostate cancer Interim Phase II data showed that men receiving AS1404 plus standard docetaxel chemotherapy had a substantially higher PSA response rate than men receiving chemotherapy alone (2/23)
Biogen Idec Inc.
(BIIB)
LumiliximabPrimatized anti-CD23 monoclonal antibody in combination with the chemotherapies, fluarabine and cyclophos- phamide plus the antibody Rituxan Chronic lymphocytic leukemiaCompany began a pivotal cancer trial (2/7)
Biomira Inc.
(Canada; BIOM;
TSX:BRA) and
Merck KGaA
(Germany)
StimuvaxLiposomal vaccine encapsulating a sequence of the MUC1 cancer mucin Non-small-cell lung cancer Enrolled the first patient in a Phase III trial (2/26)
Callisto
Pharmaceuticals
Inc.
(AMEX:KAL)
L-AnnamycinLiposomal annamycin Pediatric refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemiaStarted a Phase I trial (2/22)
Cell Genesys
Inc.
(CEGE) and
Medarex Inc.
(MEDX)
GVAXImmunotherapy administered with Medarex's anti-CTLA-4 antibody, ipilimumab (MDX-010) Prostate cancerPhase I follow-up data showed that five of six patients treated in the two highest dose groups exhibited antitumor activity including significant declines in prostate-specific antigen (2/22)
Cell
Therapeutics
Inc.
(CTIC)
XyotaxPaclitaxel poliglumex Prostate cancer Phase II data demonstrated a major response rate of 24% with a median overall survival of 8.5 months and a median time to progression of 3.5months (2/26)
ChemGenex
Pharmaceuticals
Ltd.
(Australia;
CXSP)
CeflatoninsHHT; homoharringtonine apoptosis inducer Chronic myeloid leukemiaPhase I/II data showed that all five patients that received the therapy at the highest dose and were evaluable achieved a complete hematological response, including those resistant to Gleevec (2/14)
Ciphergen
Biosystems Inc.
(CIPH)
In vitro diagnostic test To diagnose ovarian cancerStarted a trial to evaluate the triage test to differentiate women with ovarian cancer from women with benign pelvic masses (2/13)
Cougar
Biotechnology
Inc.*
CB7630Abiraterone acetate; oral inhibitor of the steroidal enzyme 17 alpha-hydroxy-lase/C17,20 lyase Prostate cancerPhase I/II data showed the drug was well tolerated at doses as high as 2,000 mg/day in the 15 patients tested, with no dose-limiting toxicity observed (2/26)
Cytogen Corp.
(CYTO)
ProstascintBrachytherapy; monoclonal antibody that targets prostate-specific membrane antigen, conjugated with indium-111 Prostate cancerData showed that the cure rate was 90.6% for patients whose fused Prostascint scan showed local disease vs. 66.1% for patients with distant disease(2/8)
Cytogen Corp.
(CYTO)
CYT-500Radiolabeled monoclonal antibody targeted to prostate-specific membrane antigen Prostate cancerBegan the first clinical study of CYT-500 (2/27)
Favrille Inc.
(FVRL)
FavIdPatient-specific immunotherapy Non-Hodgkin's lymphomaTreatment followed by high- dose chemotherapy and autologous stem cell transplantation resulted in nine of 15 patients remaining in complete remission for up to 61 months (2/12)
Genentech
Inc.
(NYSE:DNA)
Avastin (FDA-approved)Bevacizumab; antibody designed to inhibit vascular endothelial growth factor Non-small-cell lung cancer Phase III data showed that the 7.5 mg/kg and 15 mg/kg doses of Avastin produced a similar treatment effect (2/23)
Generex
Biotechnology
Corp.
(Canada;
GNBT)
AE37Peptide vaccine developed by Generex's Antigen Express division in the U.S. Breast cancer Entered a Phase II trial (2/1)
Genta Inc.
(GNTA)
GenasenseOblimersen sodium injection Relapsed or refractory chronic lymphocytic leukemiaPhase III data showed it achieved its primary endpoint, an increase over chemotherapy in those who had a complete or nodular partial response (2/14)
Genta Inc.
(GNTA)
GenasenseOblimersen sodium injectionAdvanced prostate cancerPreliminary Phase II data showed that in patients given Genasense plus docetaxel, vs. docetaxel alone, response rates proved similar (2/26)
Gloucester
Pharmaceuticals
Inc.*
RomidepsinDepsipeptide; histone deacetylase inhibitor Relapsed or refractory multiple myelomaFirst patient has been treated in a Phase I/II study of romidepsin in combination with bortezomib (2/6)
Tx Inc.
(GTXI)
AcapodeneToremifene citrate; small-molecule non-steroidal selective estrogen receptor modulator For side effects of androgen deprivation therapy and to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia An independent data safety monitoring board recommended that the company continue its two pivotal Phase III trials (2/2); Phase III interim data showed that oral, once-daily Acapodene 80 mg increased bone mineral density and lowered cholesterol (2/23)
IDM Pharma
Inc.
(IDMI)
UvidemVaccine consisting of mature dendritic cells loaded with lysates of tumor cell lines Melanoma Completed patient enrollment in two Phase II studies (2/28)
Infinity
Pharmaceuticals
Inc.
(INFI) and
MedImmune
Inc.
(MEDI)
IPI-504Heat-shock protein inhibitor Advanced non-small-cell lung cancer Started a Phase I/II trial (2/14)
Innate Pharma
SA
(France; FSE:IDD)
and Novo
Nordisk A/S
(Denmark)
IPH 2101A fully human monoclonal antibody Acute myeloid leukemiaIPH 2101 was administered into humans in a Phase I trial (2/14)**
Kosan
Biosciences Inc.
(KOSN) and
F. Hoffmann
-
La Roche Ltd.
(Switzerland)
R1492 (KOS-862)/R1645 (KOS-584)Epothilone compounds Solid tumors Discontinued development of R1492 in favor of a second- generation version called R1645, which is moving into Phase II (2/27)
Light Sciences
Oncology Inc.*
Light Infusion Therapy (Litx)Uses light-emitting diodesto activate LS11 (talaporfin sodium)Glioma Treated the first patient in its Phase II trial (2/14)
Northwest
Biotherapeutics
Inc.
(OTC BB:NWBT)
DCVax-BrainTherapy that uses a patient's own tumor, surgically removed, to prepare a mix of their personal cancer bio-markers that are loaded into the patient's dendritic cells and injected back into the patient intradermallyGlioblastoma multiformeThe first two patients have undergone surgery in the Phase II trial (2/13)
Novacea Inc.
(NOVC)
DN-101Asentar; oral, intermittent, high-dose of calcitriol designed to activate the vitamin D receptorAndrogen-independent prostate cancer Phase II data show that DN-101 might help advanced prostate cancer patients live longer while experiencing fewer chemotherapy-related side effects (2/20)
Onyx
Pharmaceuticals
Inc.
(ONXX)
Nexavar (FDA- approved)Sorafenib tablets; oral RAF kinase and VEGF inhibitor Liver cancerPhase III data showed the study met its primary endpoint earlier than expected, demonstrating superior overall survival com- pared to placebo (2/12)
Pharmion Corp.
(PHRM), GPC
Biotech AG
(Germany; GPCB)
and Spectrum
Pharmaceuticals
Inc.
(SPPI)
Satraplatin cancerA platinum-based agent; oral Hormone-refractory prostate Phase III data showed satraplatin significantly reduced the risk of disease progression (2/23)
Rigel
Pharmaceuticals
Inc.
(RIGL)
R763An oral, multi-Aurora kinase inhibitor Hematological malignanciesPartner Merck Serono started enrolling patients in a Phase I study (2/13)
Spectrum
Pharmaceuticals
Inc.
(SPPI)
EOquinApaziquone for intravesical instillationNon-invasive bladder cancerCompleted patient acrrual in a pilot safety study with 20 patients (2/6)
Threshold
Pharmaceuticals
Inc.
(THLD)
GlufosfamideSmall molecule targeting abnormal glucose metabolism Recurrent, sensitive small-cell lung cancerBegan enrolling patients in a Phase II trial (2/6)
Threshold
Pharmaceuticals
Inc.
(THLD)
GlufosfamideSmall molecule targeting abnormal glucose metabolismPancreatic cancerPhase III data showed glufosfamide missed statistical significance on its primary endpoint on improvement of overall survival compared to best supportive care in patients with metastatic disease who had relapsed after chemotherapy (2/27)
Ziopharm
Oncology Inc.
(ZIOP)
ZIO-101Organic arsenic Relapsing multiple myeloma Phase I study showed 43% of patients achieved stable disease (2/12)
CARDIOVASCULAR
ActivBiotics
Inc.
(BE:AF9)
RifalazilAnti-chlamydial antibioticAtherosclerotic changes in the carotid arteryBegan patient enrollment in a Phase II study (2/15)
BioMarin
Pharmaceutical
Inc.
(BMRN)
6R-BH4Tetrahydrobiopterin; enzyme cofactor that plays a role in the production of nitric oxideHypertensionPhase IIa data failed to show any benefit compared to placebo (2/20)
Cytori
Therapeutics
(CYTX)
Adipose-derived stem and regenerative cells Chronic myocardial ischemiaFirst patient has been treated in its randomized clinical trial (2/5)
Ilypsa Inc.*ILY101A phosphate-binding agent Hyperphos-phatemiaCompleted enrollment of its Phase II trial with 120 patients (2/6)
Pharmacopeia
Drug Discovery
Inc.
(PCOP)
PS433540A dual-acting angiotensin and endothelin receptor antagonist Hypertension and diabetic nephropathyStarted a Phase I trial (2/14)
Scios Inc.
(unit of Johnson
& Johnson
)
Natrecor (FDA-approved)Nesiritide; recombinant B-type natriuretic peptide To prevent renal dysfunction after coronary artery bypass graftingPhase II data showed that those taking Natrecor had improved outcomes after 180 days compared to patients receiving placebo (2/6)
Trigen Ltd.* (UK)Flovagatran (formerly TGN 255)An intravenous direct thrombin inhibitor ThrombocytopeniaCompleted an IND to begin a Phase III program (2/6)
United
Therapeutics
Corp.
(UTHR)
Remodulin (FDA- approved)Treprostinil sodium injection Pulmonary arterial hypertension Clinical data showed that rapid transition from intravenous epoprostenol to intravenous Remodulin in 12 patients was achieved with no serious adverse events, and baseline clinical status was maintained over 12 weeks (2/1)
ViaCell Inc.
(VIAC)
CB001Ubilical cord blood transplant therapy Blood transplants Phase I data showed the product is generally well tolerated and its outcomes were comparable to standard transplants (2/6)
CENTRAL NERVOUS SYSTEM
Adolor Corp.
(ADLR)
ADL5859Oral Delta opioid agonistPain and other conditionsStarted a Phase I trial (2/12)
Avicena Group
Inc.
(OTC BB:AVGO)
PD-02Agent that incorporates ultra-pure form of creatineParkinson's diseaseThe dose-escalating portion of a chronic toxicology study demonstrated it is safe and well tolerated; company plans to begin Phase III enrollment (2/5)
Avigen Inc.
(AVGN)
AV411Ibudilast; oral therapy; small-molecule glial attenuator that suppresses pro- inflammatory cytokines Neuropathic painPhase IIa results support a twice- daily dosing frequency (2/6)
BioLineRx Ltd.*
(Israel)
BL-1020A GABA-enhanced antipsychotic; small- molecule neuro-transmission modulatorSchizophrenia Completed Phase I trials showing the drug was well tolerated and demonstrated an improved safety profile (2/13)
Debiopharm
Group *
(Switzerland)
DEBIO-9902 SR implantsMonthly sustained-release acetylcholinesterase inhibitorAlzheimer's diseaseBegan a Phase II study (2/27)
Elite
Pharmaceuticals
Inc.
(AMEX:ELI)
ELI-216A combination of a narcotic agonist, oxycodone hydrochloride, in a sustained release formulation, and an antagonist, naltrexone hydrochloride Drug abuse Completed the first stage of a Phase II study, with results demonstrating its euphoria-blocking effect (2/15)
Halozyme
Therapeutics
(AMEX:HTI) and
Baxter Healthcare
HylenexA liquid injectable formulation that includes recombinant human hyaluronidase Pain Phase IIIb data showed positive results for the subcutaneous administration of morphine with Hylenex recombinant; it accelerated the time to maximal blood levels of morphine by 33% (2/15)
ISTA
Pharmaceuticals
Inc.
(ISTA)
Xibrom (FDA-approved)Bromfenac sodium ophthalmic solution; once-daily formulation associated with cataract surgery Post-operative ocular pain and inflammation Phase III data showed statistically significant results; ISTA plans to file a supplemental NDA (2/8)
Neurochem Inc.
(Canada; NRMX;
TSX:NRM)
AlzhemedTramiprosate; small molecule designed to interfere with association between glycosamino- glycans and A-beta protein Alzheimer's disease Completed the 18-month North American Phase III trial with 1,052 patients (2/1)
TorreyPines
Therapeutics
Inc.
(TPTX)
NGX426Prodrug of tezampanel; an AMPA/kainite receptor antagonist Pain Started a second Phase I trial to determine the maximum tolerated dose (2/26)
DIABETES
Metabasis
Therapeutics
Inc.
(MBRX)
CS-917Inhibits gluconeogenesisType II diabetes Completed enrollment in the Phase IIb trial with 392 patients (2/1)
INFECTION
Amarillo
Biosciences Inc.
(OTC BB:AMAR)
Low-dose interferon-alpha lozengesHIV-positive subjects with oral wartsBegan enrolling patients in a Phase II trial (2/8)
Antipodean
Pharmaceuticals
Inc.*
MitoQMitoquinone; antioxidants delivered by targeted lipophilic cations To reduce liver damage in patients with raised liver enzymes associated with hepatitis C virusStarted a Phase II trial with 36 patients (2/5)
Argos
Therapeutics
Inc.*
AGS-004A personalized RNA- loaded dendritic cell-based immunotherapy designed to stimulate the immune system HIVBegan a Phase I/II trial (2/9)
AspenBio
Pharma Inc.
(OTC BB:APNB)
Human appendicitis blood test To detect appendicitisClinical data shows the test can identify patients with appendicitis at a very high sensitivity level of 94% to 97%, compared to significantly lower diagnostic success rates for CT scans (2/22)
Dynavax
Technologies
Corp.
(DVAX)
TolambaDynavax's ISS molecule linked to Amb a 1, the major allergen of ragweed Ragweed allergyInterim data from the first year of a two-year trial showed a therapeutic benefit in the Midwest (2/23)
GeoVax Labs Inc.
(OTC BB:GOVX)
Vaccine AIDS preventionPhase I data indicate a good safety profile of a one-tenth dose of the vaccine, which also showed it stimulates potential protective anti-HIV-1 immune responses in the majority of recipients; a full-dose also indicated a good safety profile (2/5)
Gilead Sciences
Inc.
(GILD) and
Achillion
Pharmaceuticals
Inc.
(ACHN)
GS 9132Small-molecule inhibitor of hepatitis C virus replication Hepatitis C Companies stopped development and plan to pursue a backup compound (2/9)
Gilead Sciences
Inc.
(GILD)
GS 9137Oral HIV integrase inhibitor HIVCompleted a Phase II trial (2/26)
Human Genome
Sciences Inc.
(HGSI)
AlbuferonAlbinterferon alfa-2b; long-acting form of interferon alpha, created with albumin fusion technology Chronic hepatitis C virus genotypes 2 and 3 Started dosing in a Phase III trial of Albuferon in combination with ribavirin in treatment-naive patients (2/28)
MedImmune
Inc.
(MEDI)
FluMistInfluenza virus vaccine live, intranasalInfluenza Pivotal Phase III data showed 55% fewer cases of flu in children younger than 5 who were immunized with FluMist, compared with children who received the flu shot (2/15)
NanoBio Corp.*NB-001Topical emulsion comprised of water/oil droplets coated with an antiviral surfactant Herpes labialisStarted enrolling patients in a Phase IIb study (2/15)
Panacos
Pharmaceuticals
Inc.
(PANC)
PA-040Maturation inhibitor HIVStarted a Phase I trial (2/27)
Peregrine
Pharmaceuticals
Inc.
(PPHM)
Bavituximab (formerly Tarvacin)Anti-phosphotidylserine immunotherapeutic Chronic hepatitis C virusPhase Ib data showed it generally was safe and well tolerated and had dose-dependent antiviral activity (2/15)
Pharmasset Inc.*R7128Polymerase inhibitor; prodrug of the agent PSI-6130Hepatitis C virus genotype 1Started the multiple-ascending dose portion of an ongoing Phase I trial of R7128 in up to 40 patients chronically infected (2/28)
SciClone
Pharmaceuticals
Inc.
(SCLN)
SCV-07Oral form of synthetic dipeptide; immuno-modulatory agentViral infectious diseasesStarted a Phase II dose-ranging study (2/5)
SIGA
Technologies
Inc.
(SIGA)
SIGA-246Orally active antiviral agentSmallpox Launched a multiple-dose Phase I trial (2/13)
Targeted
Genetics
Corp.
(TGEN)
tgAAC09Preventive vaccine based on HIV subtype C; uses a recombinant adeno-associated viral vectorHIVPhase I data in 80 healthy volunteers show that a single intra- muscular injection appears to be safe and well tolerated and stimulated a modest immune response against gag, the principal HIV protein encoded by tgAAC09 (2/28)
The Immune
Response Corp.
(OTC BB:IMRP)
Remune

and IR103

First- and second-generation HIV vaccine candidates; IR103 is a co- formulation of Remune and Amplivax, a TLR-9 agonist adjuvant HIVPhase II data suggested that both Remune and IR103 stabilize CD4+ T-cell counts compared to placebo in HIV patients who have not started antiretroviral therapy (2/15)
Tibotec
Pharmaceuticals
Ltd.
(Belgium; unit
of Johnson & Johnson)
and Medivir AB
(Sweden; SSE:MVIRB)
NS3/4A protease inhibitor Hepatitis C virusStarted a Phase I trial (2/8)
MISCELLANEOUS
Aastrom
Biosciences
Inc.
(ASTM)
Tissue Repair CellsA mixture of stem and progenitor cells derived from the patient's bone marrowSevere long bone fracturesCompany said 90% of patients who have completed the 12 months post-treatment follow-up of a Phase I/II trial have evidence of bone regeneration (2/14)
Advanced
BioHealing Inc.*
CeladermNext-generation bio-engineered tissue productVenous leg ulcersEnrolled the first patient in a pilot study (2/8)
Amarin Corp.
plc
(UK; AMRN)
MiraxionCompound that inhibits certain enzymes, including phospholipases and caspasesHuntington's diseaseCompleted the treatment phase of the North American and the European Phase III trials (2/5)
Ambrx Inc.*ARX201A next-generation human growth hormone candidateGrowth hormone deficiencyStarted a Phase I/II trial (2/12)
Arena
Pharmaceuticals
Inc.
(ARNA)
Lorcaserin hydrochloride

ObesityCompleted enrollment in the first of three planned Phase III trials (2/5)
Arpida Ltd.
(Switzerland;
SWX:ARPN)
and obesity
IclaprimIntravenous formulation of broad-spectrum antibioticRenal and hepatic impairmentPhase I data confirmed the drug was safe and well tolerated (2/8)
Auxilium
Pharmaceuticals
Inc.
(AUXL)
AA4500Injectable enzyme productDupuytren's contracturePhase III data demonstrated the drug reduced joint contracture in both the double-blind and open-label phases of the trial (2/20)
Basilea
Pharmaceutica
Ltd.
(Switzerland;
SWX:BSLN)
AlitretinoinNaturally occurring vitamin A derivativeSevere and refractory chronic hand dermatitisPhase III data showed that of the patients receiving 30 mg, 48% achieved the primary endpoint of clear or almost clear skin, compared to 28% in the 10 mg group and 17% in the placebo group (2/20)
Ceragenix
Pharmaceuticals
Inc.
(OTC
BB:CGXB)
EpiCeramMid-strength topical steroidModerate to severe atopic dermatitisCompleted the patient visit phase of a clinical study with 112 children (2/21)
Columbia
Laboratories
Inc.
(CBRX)
Prochieve (FDA-approved)Progesterone gelPreterm birth Failed to reduce the incidence of preterm birth in a Phase III study (2/5)
Dynogen
Pharmaceuticals
Inc.*
DDP733An oral partial agonist of the serotonin Type 3 receptor Irritable bowel syndromePhase II data showed the drug achieved a statistically significant overall clinical response rate of 54% in those receiving 1.4mg t.i.d. compared to 15% for the placebo group (2/13)
Emisphere
Technologies
Inc.
(EMIS),
Novartis Pharma
AG
(Switzerland)
and Nordic
Bioscience
(Denmark)
Salmon calcitoninOral formulation that uses Emisphere's eligen-delivery technologyOsteoporosis Novartis and Nordic started a Phase III trial (2/27)
InSite Vision Inc.
(AMEX:ISV)
AzaSite PlusISV-502; a combination antibiotic/corticocosteroid product formulated in DuraSiteInflammation and infection of the eyeTop-line Phase I data showed the product was well tolerated, with no serious adverse events reported (2/13)
Intercytex plc
(LSE:ICX)
ICX-SKNA skin graft substitute comprised of active, allogeneic, human dermal fibroblasts embedded in a human collagen matrixFor skin graftsStarted a Phase I trial (2/21)**
Kuros
Biosurgery AG*
(Switzerland)
and Baxter
Healthcare
An injection that uses Kuros' technology for binding biologics within Baxter's fibrin-based biomatrix, TISSEEL Fibrin SealantTibial plateau fracturesStarted a Phase II trial (2/5)
Manhattan
Pharmaceuticals
Inc.
(AMEX:MHA)
OleoylestroneOral therapy; synthetic formulationObesityCompleted patient enrollment in a Phase IIa study (2/21)
MAP
Pharmaceuticals
Inc.*
MAP0010Nebulized formulation of budesonide for inhalation AsthmaPhase II data showed it met its primary efficacy endpoints of asthma control as assessed by changes in morning asthma symptom scores compared to placebo (2/27)
Marinus
Pharmaceuticals
Inc.*
GanaxoloneSynthetic version of naturally occurring neuroactive steroids (epalons) that bind to gamma aminobutyric acid (GABA)-A receptors in brainInfantile spasms Dosed the first patient in an international, randomized Phase IIb study (2/28)
Nymox
Pharmaceutical
Corp.
(NYMX)
NX-1207Investigational agent for BPH Benign prostatic hyperplasiaCompleted a long-term follow-up study of NX-1207 (2/28)
OrthoLogic
Corp.
(OLGC)
ChrysalinA synthetic peptide that mimics certain attributes of the thrombin molecule Unstable, displaced wrist fractures Phase III data showed that a subset of female osteopenic subjects treated with 10 mcg of Chrysalin demonstrated a statistically significant benefit compared to placebo in the primary endpoint of time to removal of immobilization (2/19)
Osiris
Therapeutics
Inc.
(OSIR)
ChondrogenAdult stem cells formulated for direct injection To regenerate cartilage in the kneeSix-month results from a Phase I/ II trial showed Chondrogen met its primary endpoint of safety, but did not show a statistically significant increase in the volume of meniscus as compared to placebo (2/13)
OxiGene Inc.
(OXGN)
CA4PCombretastatin A4 Phosphate; vascular disrupting agent Myopic macular degenerationPhase II data showed it met its primary efficacy endpoint of maintenance of visual acuity in 100% of patients, and safety results were favorable (2/15)
Palatin
Technologies
Inc.
(AMEX:PTN)
and King
Pharmaceuticals
Inc.
BremelanotideMelanocortin receptor agonist Female sexual arousal disorderPhase IIa data show that 73% of women receiving bremelano- tide reported an increased level of genital arousal vs. 23% on placebo (2/26)
Pharmacopeia
Drug Discovery
Inc.
(PCOP) and
Schering-Plough
Corp.
PS522501A compound in development for metabolic diseaseMetabolic diseasesStarted a Phase I trial (2/20)
Pharmaxis Ltd.
(Australia; PXSL)
BronchitolMannitol formulation delivered via an inhalation deviceBronchiectasis Company reached the recruitment target of 354 subjects in its Phase III trial (2/2)
Regeneron
Pharmaceuticals
Inc.
(REGN)
IL-1 TrapInterleukin-1 rilonacept Cryopyrin-associated periodic syndromesProduct met its primary endpoint in the change of disease activity in a Phase III study (2/28)
Quark Biotech
Inc.*
and
SR Pharma plc
(UK)
RTP-801iSmall interfering RNA therapeuticAge-related macular degenerationStarted a Phase I trial (2/5)
TargeGen Inc.*TG100801Topical, small-molecule multitarget kinase inhibitor Macular degeneration and other eye diseasesCompleted a Phase I trial in 42 healthy volunteers (2/28)
Zelos
Therapeutics
Inc.
(ASX:ZCO)
Ostabolin-CA parathyroid hormone analogue OsteoporosisTop-line Phase II results showed that it demonstrated a statistically significant, dose response increase in mean lumbar spine bone mineral density that reached 5.2% at the highest dose tested (2/8)

Notes:
* Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.
AMEX = American Stock Exchange; BE = Berlin Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSX = Toronto Stock Exchange.

No Comments